Preferences help
enabled [disable] Abstract
Number of results
2018 | 8 | 4 | 108-113
Article title

Erythropoietin and the erythropoietin receptor, and drug resistance and progression of the neoplastic disease

Title variants
Languages of publication
Preclinical studies conducted over the past 10 years have shown that EPO is not only a hormone that regulates erythropoiesis, a major growth factor, but also a cytoplasm with pleiotropic activity that also affects cancer cells. The expression of EPO and its receptor (EPOR) occurs in many cancers of various origins. The EPO/EPOR system is active in many cancer cells and is involved in the modification of molecular signaling pathways and the stimulation of growth, survival, motility and the ability to create metastases. EPO can also increase the resistance of cancer cells in vitro and in vivo to chemotherapy and radiotherapy.

Physical description
  • 1st Radiation and Clinical Oncology Department, Maria Sklodowska-Curie Institute of Oncology, Gliwice, Poland,
  • Department of Bone Marrow Transplantation and Hematology-Oncology, Maria Sklodowska-Curie Institute of Oncology, Gliwice, Poland
  • 1st Radiation and Clinical Oncology Department, Maria Sklodowska-Curie Institute of Oncology, Gliwice, Poland
  • 1st Radiation and Clinical Oncology Department, Maria Sklodowska-Curie Institute of Oncology, Gliwice, Poland
  • 1st Radiation and Clinical Oncology Department, Maria Sklodowska-Curie Institute of Oncology, Gliwice, Poland
  • 1. Radziwon P, Krzakowski M, Kalinka-Warzocha E et al. Niedokrwistość u chorych na nowotwory. Onkol Prakt Klin 2017; 3: 1-10.
  • 2. Della Ragione F, Cucciolla V, Borriello A et al. Erythropoietin receptors on cancer cells: a still open question. J Clin Oncol 2007; 25: 1812-1813.
  • 3. Acs G, Acs P, Beckwith SM et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001; 61: 3561-3565.
  • 4. Henke M, Laszig R, Rube C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double- blind, placebo-controlled trial. Lancet 2003; 362(9392): 1255-1260.
  • 5. Vaupel P, Mayer A, Hockel M. Impact of hemoglobin levels on tumor oxygenation: The higher, the better? Strahlenther Onkol 2006; 182: 63-71.
  • 6. Chretien S, Moreau-Gachelin F, Apiou F et al. Putative oncogenic role of the erythropoietin receptor in murine and human erythroleukemia cells. Blood 1994; 83: 1813-1821.
  • 7. Ferreira DB, da Costa WH, Clavijo DA et al. Tissue Expression of Erythropoietin Predicts Survival Rates in Clear Cell Renal Cell Carcinoma. Kidney Cancer 2017; 1(2): 143-149.
  • 8. Horvath-Puho E, Suttorp MM, Frederiksen H et al. Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma. Clin Epidemiol 2018; 10: 1371-1380. DOI: 10.2147/CLEP.S172306.
  • 9. Todaro M, Turdo A, Bartucci M et al. Erythropoietin activates cell survival pathways in breast cancer stem-like cells to protect them from chemotherapy. Cancer Res 2013; 73: 6393-6400.
  • 10. Hedley BD, Chu JE, Ormond DG et al. Recombinant human erythropoietin in combination with chemotherapy increases breast cancer metastasis in preclinical mouse models. Clin Cancer Res 2011; 17: 6151-6162.
  • 11. Kirkeby A, Van BJ, Nielsen J et al. Functional and immunochemical characterisation of different antibodies against the erythropoietin receptor. J Neurosci. Methods 2007; 164: 50-58.
  • 12. Elliott S, Busse L, Bass MB et al. Anti-Epo antibodies do not predict Epo receptor expression. Blood 2006; 107: 1892-1985.
  • 13. Swift S, Ellison AR, Kassner P et al. Absence of functional EpoR expression in human tumor cell lines. Blood 2010; 115: 4254-4263.
  • 14. Zhou Y, Sakurai H. Emerging and Diverse Functions of the EphA2 Noncanonical Pathway in Cancer Progression. Biol Pharm Bull 2017; 40(10): 1616-1624.
  • 15. Szenajch J, Synowiec A. Erytropoetyna a lekooporność w raku piersi i raku jajnika. Ginekol Pol 2016; 87: 300-304.
  • 16. Larsson AM , Jirstrom K, Fredlund E et al. Erythropoietin receptor expression and correlation to tamoxifen response and prognosis in breast cancer. Clin Cancer Res 2009; 15: 5552-5559.
  • 17. Pelekanou V, Kampa M, Kafousi M et al. Erythropoietin and its receptor in breast cancer: correlation with steroid receptors and outcome. Cancer Epidemic. Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 2007; 16: 2016-2023.
  • 18. Reinbothe S, Larsson AM , Vaapil M et al. EPO-independent functional EPO receptor in breast cancer enhances estrogen receptor activity and promotes cell proliferation. Biochem Biophys Res Commun 2014; 445: 163-169.
  • 19. Liang K, Esteva FJ, Albarracin C et al. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell 2010; 16: 423-435.
  • 20. Badve S, Nakshatri H. Breast-cancer stem cells-beyond semantics. Lancet Oncol 2012; 13: 43-48.
  • 21. Canapro R, Casale F, Muntoni E et al. Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy. Br J Clin Pharmacol 2000; 50: 146-153.
  • 22. Vazquez-Mellado MJ, Cortes-Ballinas LG , Blanco-Flores IC et al. Erythropoietin promotes expression of survivin via STAT 3 activation and reduces sensitivity to cisplatin in cervical cancer cells. Oncol Rep 2018. DOI: 10.3892/or.2018.6890.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.